Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238635 · ClinicalTrials.gov registry record · Phase 2
Dostarlimab and Cobolimab in Advanced Cervical Cancer
A Phase 2 study of Cervical Cancer and Recurrent Cervical Carcinoma, sponsored by Meghan Shea.
- Active
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 2
- Study locations
NCT06238635: Active Phase 2 study of Cervical Cancer and Recurrent Cervical Carcinoma, sponsored by Meghan Shea.
NCT06238635 is a Phase 2 study of Cervical Cancer and Recurrent Cervical Carcinoma that is active but no longer recruiting, run by Meghan Shea. The registered enrollment target is 66 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06238635, a Phase 2 study of Cervical Cancer and Recurrent Cervical Carcinoma, is active but no longer recruiting, sponsored by Meghan Shea.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
Primary Outcome
ORR based on irRECIST is defined as the proportion of participants who achieved partial response or complete response during study treatment based on immune-related RECIST criteria.
Conditions Studied
Interventions
- DRUG Dostarlimab
- DRUG Cobolimab
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 2 |
What the registry record for NCT06238635 still lists
NCT06238635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (88% lower).
The record links to 5 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Dostarlimab is the first listed.
NCT06238635 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06238635 about?
NCT06238635 is a clinical study titled "Dostarlimab and Cobolimab in Advanced Cervical Cancer". This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
What is the current status of trial NCT06238635?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-03-11. Estimated completion is 2027-07-15.
What conditions does trial NCT06238635 study?
This clinical trial studies the following conditions: Cervical Cancer, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Advanced Cervical Carcinoma.
What interventions are being tested in trial NCT06238635?
The interventions under investigation include: Dostarlimab (DRUG), Cobolimab (DRUG).
Who is sponsoring clinical trial NCT06238635?
This trial is sponsored by Meghan Shea, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238635 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06238635's enrollment target sits among peer trials
66 85th of 144 higher than 60 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI